icatibant (Firazyr)
Jump to navigation
Jump to search
Indications
- symptomatic treatment of acute attacks of hereditary angioedema (FDA-approved Aug 2011)
- useful for treatment of ACE-inhibitor induced angioedema[3]
- median time to resolution = 8 hours
Dosage
- prefilled syringe, 3 mL (30 mg), SQ, preferably abdomen
- a 2nd injection may be given 6 hours after the 1st
- maximum: 3 injections/day
Mechanism of action
- specific antagonist of bradykinin B2 receptors
More general terms
References
- ↑ Wikipedia: Icatibant http://en.wikipedia.org/wiki/Icatibant
- ↑ Walker EP FDA Approves Icatibant for Rare Swelling Condition http://www.medpagetoday.com/ProductAlert/Prescriptions/28193
- ↑ 3.0 3.1 Bas M et al A Randomized Trial of Icatibant in ACE-Inhibitor-Induced Angioedema. N Engl J Med 2015; 372:418-425. January 29, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25629740 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1312524
- ↑ icatibant http://www.drugs.com/mtm/icatibant.html
- ↑ Package Insert http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000899/WC500022966.pdf